Per chi non avesse ancora capito, questa mossa del governo Trump in pratica elimina la possibilità di nuovi vaccini. Quasi nessuno dei vaccini esistenti potrebbe passare test clinici dimostrando sicurezza ed efficacia contro un placebo. È un atto talmente rivoluzionario che stento ancora a crederci. E mi domando come potranno venire approvati nel resto del mondo dei "vaccini" non approvati negli USA. For those who haven't figured it out yet, this move by the Trump administration essentially eliminates the possibility of new vaccines. Almost none of the existing vaccines could pass clinical trials demonstrating safety and efficacy against a placebo. This is such a revolutionary act that I still can't believe it. And I wonder how "vaccines" not approved in the US could be approved in the rest of the world. Source: https://x.com/MarcoDabizzi/status/1918177376753860627?t=96j7WrR4qYtLAdwCs18B4A&s=19

The global Breast Cancer Therapy Market is witnessing significant momentum as innovative treatment approaches, rising disease awareness, and supportive healthcare policies converge to redefine patient outcomes. With an increasing number of breast cancer cases reported worldwide, the demand for effective diagnostic and therapeutic solutions continues to rise, driving rapid advancements in oncology treatment protocols. Market Overview The global Breast Cancer Therapy market size is expected to reach USD 63.13 billion by 2032, according to a new study by Polaris Market Research. The market encompasses a wide range of treatment modalities including chemotherapy, hormonal therapy, targeted therapy, immunotherapy, and radiation therapy. Key therapeutic innovations and rising investment in cancer research are accelerating market growth, with emerging players and established pharmaceutical companies launching new drug formulations and personalized treatments. Key Market Growth Drivers 1. Rising Global Incidence of Breast Cancer According to the World Health Organization (WHO), breast cancer has surpassed lung cancer as the most commonly diagnosed cancer globally. In 2024 alone, over 2.3 million women were diagnosed with breast cancer, making it a leading cause of cancer-related deaths among females. This soaring incidence is a primary driver of therapy demand, leading to increased screening programs and early detection initiatives. 2. Advancements in Targeted and Immunotherapies Breakthroughs in targeted therapy and cancer immunotherapy are transforming the treatment landscape. Medications like trastuzumab, pertuzumab, palbociclib, and newer checkpoint inhibitors offer improved efficacy and fewer side effects compared to traditional chemotherapy. The integration of biomarkers and companion diagnostics has further enhanced the precision of treatment delivery. 3. Government and Private Sector Investment Growing government support and private sector funding in oncology research and clinical trials are fueling the development of novel breast cancer drugs. Initiatives such as the Cancer Moonshot program in the United States and the EU’s Horizon Europe research funding have mobilized substantial resources for cancer therapy innovation. 4. Rising Awareness and Early Detection Campaigns Public health campaigns, advocacy by non-profits such as the Susan G. Komen Foundation and Breast Cancer Now, and corporate social responsibility initiatives are boosting awareness, reducing stigma, and encouraging early screening. Earlier diagnosis significantly improves treatment outcomes, thereby increasing the adoption of therapy solutions. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: https://www.polarismarketresearch.com/industry-analysis/breast-cancer-therapy-market Market Challenges Despite the growth trajectory, the breast cancer therapy market faces several obstacles: 1. High Treatment Costs Advanced therapies, particularly biologics and immunotherapies, come with high price tags. The cost burden poses challenges for patients in low-income regions and contributes to inequality in access to treatment. Even in developed economies, the affordability of newer therapies remains a concern for uninsured or underinsured populations. 2. Adverse Effects and Drug Resistance Chemotherapy and radiation therapy often lead to severe side effects, such as nausea, fatigue, and hair loss, affecting the patient’s quality of life. Additionally, drug resistance in metastatic breast cancer limits the long-term effectiveness of certain treatments, prompting the need for ongoing drug innovation and combination therapies. 3. Complex Regulatory Approvals Securing regulatory approvals for new cancer drugs involves rigorous clinical testing and time-intensive documentation. Delays in approval can restrict the timely introduction of promising treatments into the market. 4. Limited Access in Emerging Economies Healthcare infrastructure challenges in many developing countries, along with lack of trained oncologists and inadequate insurance coverage, limit the adoption of advanced breast cancer therapies in these regions. Regional Analysis North America North America holds the largest share of the global market, driven by high awareness, early diagnosis rates, and the availability of advanced healthcare infrastructure. The United States, in particular, is a dominant player, with strong R&D activity, a robust clinical trial pipeline, and the presence of major pharmaceutical companies like Pfizer, Roche, and Eli Lilly. Europe Europe is the second-largest market, with countries such as Germany, France, and the United Kingdom showing strong demand for targeted and hormonal therapies. Government-funded cancer research programs and national screening guidelines contribute to market expansion. Asia Pacific The Asia Pacific region is experiencing the fastest growth due to rising cancer prevalence, improved access to healthcare, and increased investment by global pharmaceutical companies. China, India, and Japan are emerging as high-potential markets, particularly in urban centers where awareness and healthcare access are improving. Latin America & Middle East These regions are gradually expanding due to enhanced health policies and international health aid. However, limited access to advanced therapies and diagnostic tools remains a hurdle. Key Companies in the Breast Cancer Therapy Market Several leading companies are at the forefront of innovation and market development: 1. Roche Holding AG Roche is a global leader in oncology, with a robust portfolio that includes Herceptin, Perjeta, and Kadcyla. The company continues to invest heavily in targeted therapies and personalized treatment approaches. 2. Pfizer Inc. Pfizer has significantly contributed to the breast cancer treatment space with drugs like Ibrance (palbociclib), a CDK 4/6 inhibitor that has changed the standard of care for HR-positive, HER2-negative metastatic breast cancer. 3. AstraZeneca AstraZeneca’s focus on precision oncology is evident in its pipeline of antibody-drug conjugates (ADCs) and the success of Enhertu, developed in partnership with Daiichi Sankyo. The company is also exploring combination therapies to overcome drug resistance. 4. Eli Lilly and Company Eli Lilly has expanded its oncology portfolio with Verzenio (abemaciclib), another CDK4/6 inhibitor that has shown promise in both early-stage and advanced breast cancer cases. 5. Novartis AG Novartis plays a major role with its Kisqali (ribociclib) and a deep research pipeline targeting hormone receptor-positive subtypes. The company emphasizes access programs in low- and middle-income countries. 6. Gilead Sciences Gilead entered the breast cancer therapy space through its acquisition of Immunomedics and its groundbreaking ADC, Trodelvy, targeting triple-negative breast cancer. Future Outlook The breast cancer therapy market is poised for transformative change as new technologies—including AI-driven diagnostics, genomic profiling, and nanotechnology-based drug delivery systems—gain traction. Moreover, as personalized medicine becomes more central to oncology treatment strategies, the focus will shift to tailored drug combinations, real-world evidence integration, and patient-centric care models. More Trending Latest Reports By Polaris Market Research: Hair Styling Products Market Guns and Accessories Market Hematologic Malignancies Therapeutics Market Thermal Spray Coatings Market Latin America Industrial Pumps Market Enteric Empty Capsules Market Snow Sport Accessories Market High Frequency Trading Servers Market Vascular Stent Market

The electric commercial vehicle (ECV) market is experiencing unprecedented growth, driven by advancements in battery technology, supportive government policies, and the global shift towards sustainable transportation solutions. The global electric commercial vehicle market size is expected to reach USD 356.25 billion by 2032, according to a new study by Polaris Market Research. Market Overview Electric commercial vehicles, including electric trucks, vans, and buses, offer a sustainable alternative to traditional fossil fuel-powered vehicles. These vehicles are powered by rechargeable batteries, reducing greenhouse gas emissions and contributing to cleaner urban environments. The increasing adoption of ECVs is fueled by stringent emission regulations, rising fuel costs, and the need for cost-effective logistics solutions. The market's expansion is further supported by technological advancements in battery management systems, electric drivetrains, and regenerative braking systems. These innovations enhance the efficiency, range, and performance of ECVs, making them viable for a wide range of commercial applications. Market Segmentation The electric commercial vehicle market can be segmented based on vehicle type, propulsion type, battery capacity, end-use industry, and region. 1. Vehicle Type: Light Commercial Vehicles (LCVs): These include electric vans and pickups used for urban deliveries and last-mile logistics. Medium and Heavy-Duty Trucks: These vehicles are employed for regional and long-haul transportation, offering higher payload capacities. Electric Buses: Used for public transportation, these buses contribute to reducing urban air pollution. 2. Propulsion Type: Battery Electric Vehicles (BEVs): Fully electric vehicles powered by rechargeable batteries. Plug-in Hybrid Electric Vehicles (PHEVs): Vehicles that combine an internal combustion engine with an electric motor, allowing for extended range. 3. Battery Capacity: Below 100 kWh: Suitable for short-distance urban deliveries. 100–300 kWh: Ideal for regional transportation needs. Above 300 kWh: Designed for long-haul applications requiring extended range. 4. End-Use Industry: Logistics and Warehousing: Adoption of ECVs for efficient goods transportation. Public Transportation: Deployment of electric buses for sustainable urban mobility. E-commerce and Retail: Use of electric vans for last-mile deliveries. Regional Analysis Asia Pacific: Dominating the global ECV market, the Asia Pacific region accounted for 55.8% of the market share in 2022 . China, in particular, leads in ECV adoption, driven by government incentives, stringent emission norms, and a robust manufacturing base. The proliferation of e-commerce and last-mile delivery services further fuels demand for electric commercial vehicles. Europe: The European market is witnessing significant growth, with countries like Germany, the Netherlands, and the UK leading the adoption of electric commercial vehicles. Government policies such as the EU’s Fit for 55 Plan and incentives for zero-emission vehicles contribute to the market's expansion. North America: The United States and Canada are investing heavily in electric vehicle infrastructure and offering tax incentives to promote ECV adoption. Companies like Tesla, Rivian, and Ford are at the forefront of developing electric commercial vehicles tailored for the North American market. Key Players in the Market Several companies are leading the charge in the electric commercial vehicle market: BYD (China): A global leader in electric vehicles, BYD manufactures a range of electric buses and trucks. Mercedes-Benz Group AG (Germany): Offers the eActros electric truck, catering to the European market. AB Volvo (Sweden): Provides electric trucks and buses, focusing on sustainability and innovation. Ford Motor Company (USA): Develops electric delivery vans and trucks, including the E-Transit and F-150 Lightning. Rivian (USA): Specializes in electric adventure vehicles and commercial delivery vans. Tesla (USA): Known for the Tesla Semi, an all-electric Class 8 truck designed for long-haul freight. Technological Advancements Advancements in battery technology are pivotal to the growth of the electric commercial vehicle market. The adoption of lithium-ion batteries, particularly NMC (Nickel Manganese Cobalt) batteries, offers higher energy density and longer lifespan, enhancing the range and efficiency of ECVs . Additionally, the development of fast-charging infrastructure and battery swapping stations addresses range anxiety and reduces downtime for commercial fleets. Integration of renewable energy sources with charging stations further promotes the sustainability of electric commercial vehicles. Challenges and Opportunities While the electric commercial vehicle market presents significant growth prospects, challenges such as high initial costs, limited charging infrastructure, and range limitations persist. However, ongoing research and development efforts, coupled with supportive government policies, are expected to mitigate these challenges. Opportunities lie in the development of affordable electric commercial vehicles, expansion of charging networks, and integration of smart technologies such as vehicle-to-grid systems and autonomous driving capabilities. Conclusion The electric commercial vehicle market is poised for transformative growth, driven by technological innovations, supportive policies, and the global shift towards sustainable transportation solutions. As governments and industries collaborate to overcome existing challenges, the widespread adoption of electric commercial vehicles will contribute to cleaner, more efficient, and cost-effective transportation systems worldwide. More Trending Latest Reports By Polaris Market Research: Cryptocurrency Market Virtual Clinical Trials Market- update Pharmaceutical Aseptic Transfer Market Piezoelectric Devices Market Organic Rankine Cycle Market FEP Heat Shrink Medical Tubing Market Camera Modules Market Painting Robots Market Queue Management System Market

MA COSA AVETE INIETTATO AI NEONATI E BAMBINI??? @BeaLorenzin Aaron Siri: "Nessun vaccino infantile... è stato sottoposto a una sperimentazione clinica controllata con placebo di durata sufficiente... per valutarne la sicurezza prima di essere iniettato a milioni di bambini in America." BUT WHAT HAVE YOU INJECTED INTO NEWBORNS AND CHILDREN??? @BeaLorenzin Aaron Siri: "No childhood vaccine... has undergone a placebo-controlled clinical trial of sufficient length... to evaluate its safety before being injected into millions of children in America." Source: https://x.com/wideawake_media/status/1916417171967627436?t=e5CQDB8zupZSMmmrp1jV1w&s=19

https://www.databridgemarketresearch.com/pt/reports/global-clinical-trial-consumables-market

https://www.databridgemarketresearch.com/ko/reports/global-clinical-trial-consumables-market

https://www.databridgemarketresearch.com/jp/reports/global-clinical-trial-consumables-market

https://www.databridgemarketresearch.com/jp/reports/global-clinical-trial-consumables-market

STANNO SVILUPPANDO "VACCINI" A MRNA PER LA MALARIA Diverse università e ditte, tra cui Biontech, stanno provando a produrre un veleno a mRNA per la malaria per lucrare sugli africani e nel frattempo sfoltirli un po'. 1) ADIUVANTE TOSSICO L'obiettivo dello studio, che trovate qui (https://t.me/dereinzige2/1276), dovrebbe essere l'aumento di cellule T residenti nel fegato, e iniettando come antigene da far sintetizzare tramite mRNA la ovalbumina del pollo e l'antigene della malaria RPL6, è stato visto che le risposte del sistema immunitario erano nulle. Quindi hanno aggiunto come adiuvante l'αGC, un nanolipide che ha portato ad una produzione di cellule natural killer. Il problema di questo adiuvante è la tossicità per il fegato (https://www.nature.com/articles/nri35095523.pdf), perché topi a cui è stato somministrato hanno sviluppato necrosi epatica (https://www.nature.com/articles/bjc2014486). Se somministrato a topi sotto stimolazione della via beta adrenergica comporta un'irreversibile fibrosi miocardica (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656804/), ipertrofia cardiaca e fibrosi renale (https://pubmed.ncbi.nlm.nih.gov/34243040/), il veleno Pfizer di per sé porta ad un aumento delle catecolamine (https://t.me/dereinzigeitalia/508) che agiscono come un fattore di stimolazione di questa via. L'αGC può portare all'aterosclerosi (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618636/) e rendere le placche più instabili, e una rottura di queste può causare una trombosi. L'accumulo di cellule natural killer nel sangue in seguito alla stimolazione da αGC è altamente infiammatorio (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618636/), e un'elevata dose di questo adiuvante può esacerbare e rendere suscettibili all'encefalomielite (https://pubmed.ncbi.nlm.nih.gov/20084083/). Sull'uomo questo adiuvante è ancora sperimentale, ma quanto detto fin ora non fa ben sperare. 2) IL VACCINO BIONTECH Nonostante lo studio precedente sia un nulla di fatto perché non ha studiato nemmeno l'efficacia vaccinale, si possono trovare articoli come questi (1, 2) che fanno propaganda di questi veleni a mRNA per la malaria, addirittura anteponendo i vaccini alle cure per far risparmiare soldi agli stati. Persino Biontech ha già iniziato la sperimentazione umana (https://classic.clinicaltrials.gov/ct2/show/NCT05581641) di un suo prodotto a mRNA dove si utilizzano esseri umani come carne da macello (1, 2, 3, 4, 5) e già sono partiti con 3 dosi. La base per questa sperimentazione è un singolo studio preclinico (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213722/) sui topi dove questa volta l'antigene è la proteina PfCSP, e anche in questo case l'efficacia è un misero 40% contro lo sviluppo dell'infezione dopo 2 dosi. Con la terza dose l'efficacia sale al 60%, valore ancora basso, ed è stata studiata solo per 14 giorni. Anche in questo caso gli adiuvanti sono problematici, perché sono simili a quelli usati per il veleno Pfizer, e quindi se usati sugli esseri umani avranno le stesse dannose conseguenze (https://t.me/dereinzigeitalia/499) sul sistema immunitario. Note: 1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166207/ 2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041686/ 1. https://www.voaafrica.com/a/biontech-begins-human-trial-to-test-malaria-vax/6888702.html 2. https://www.gavi.org/vaccineswork/hunting-perfect-protein-malaria-mrna-vaccine 3. https://www.biopharma-reporter.com/Article/2022/07/12/biontech-set-to-take-malaria-vaccine-into-clinical-trials 4. https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-initiates-clinical-trial-mrna-based-malaria-vaccine-candidate-2022-12-23/ 5. https://www.clinicaltrialsarena.com/news/biontech-vaccine-candidate-malaria/ 3) LA MALARIA SI PUÒ CURARE L'inoculazione di prodotti sperimentali è del tutto insensata, a maggior ragione perché esistono attualmente dei trattamenti efficaci per la malaria. In linea di massima si può usare la clorochina, ma se il ceppo di malaria ha sviluppato resistenza (https://jamanetwork.com/journals/jama/article-abstract/2794759) è più indicata l'artemisinina, oppure proguanil, quinina e clindamicina. Il trattamento della Malaria infatti si basa principalmente sull'adattare l'uso di questi farmaci (https://www.aafp.org/pubs/afp/issues/2022/0900/malaria.html) in base al ceppo di provenienza del parassita, perché in diverse regioni può aver sviluppato diverse resistenze ai farmaci. In quei casi in cui si dovesse sviluppare una malaria grave, il trattamento invece è l'artesunato da somministrare per via endovenosa (https://www.ncbi.nlm.nih.gov/books/NBK294445/#ch7.s6) per poi passare alle terapie già menzionate. I pro vax sicuramente obietterebbero dicendo che il vaccino è preferibile perché a furia di trattare la malaria coi farmaci si sviluppa farmacoresistenza, ma in realtà un fenomeno analogo, ancor più grave perché porta alla selezione di nuove varianti (https://t.me/dereinzigeitalia/527), può succedere con qualsiasi tipo di vaccino. CONCLUSIONI Big Pharma col covid in Africa ha potuto fare pochi affari, e quindi adesso vogliono avere la loro rivalsa usando la malaria, una patologia che è sempre stata problematica in Africa, e sfruttando la tendenza che gli africani rifiutano meno i vaccini per la malaria rispetto ai vaccini per altre patologie. In questo modo quello che hanno fatto qui con il veleno Pfizer potranno farlo lì con l'equivalente della malaria. Fonte Canale Telegram: https://t.me/dereinzigeitalia